Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04747977 · ClinicalTrials.gov registry record · Phase 2
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
A Phase 2 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT04747977 is a Phase 2 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 172 participants.
The verdict
NCT04747977, a Phase 2 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
Interventions
- DRUG OTX-DED
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2021-02-12 |
| Est. Completion | 2021-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04747977
The ClinicalTrials.gov registry entry for NCT04747977 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OTX-DED is the first listed.
NCT04747977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04747977 about?
NCT04747977 is a clinical study titled "To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease". To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
What is the current status of trial NCT04747977?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2021-02-12. Estimated completion is 2021-09-22.
What interventions are being tested in trial NCT04747977?
The interventions under investigation include: OTX-DED (DRUG).
Who is sponsoring clinical trial NCT04747977?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.